http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Effect of CdS contents on H_2 production from Pt-(CdS/TiO_2) film-typed photocatalysts
Eunpyo Hong,김정현,Jin Hyun Kim,Sunhye Yu 한국화학공학회 2011 Korean Journal of Chemical Engineering Vol.28 No.8
Pt-(CdS/TiO_2) film-typed photocatalysts are prepared with a doctor-blade method followed by a chemical bath deposition (CBD) process, and the films are characterized by UV-vis spectroscopy, scanning electron microscopy,energy-dispersive X-ray spectroscopy. The film-typed structure is composed of photocatalysts and Pt metal part on a FTO substrate without additional electric device, so it is relatively simpler than the conventional photoelectrochemical cell. CdS quantum dots are introduced as a sensitizer for visible light response. Amounts of CdS quantum dots on TiO_2 surface are increased with increasing CBD cycles, but they start to aggregate after certain CdS concentration due to oversaturation phenomenon. This high CdS content induces high electron losses, and therefore it reduces amounts of hydrogen production. As a result, there is a saturation point of CdS content at Cd/Ti ratio of 0.197, and the amounts of evolved hydrogen are 5.407 μmol/cm^2 ·h at this photocatalyst formulation.
Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014)
Lee, Yoonji,Hong, Sunhye,Cui, Minghua,Sharma, Pankaz K,Lee, Jeewoo,Choi, Sun Informa UK, Ltd. 2015 Expert opinion on therapeutic patents Vol.25 No.3
<P>Introduction: Transient receptor potential vanilloid type 1 (TRPV1) is a nonselective cation channel that can be activated by noxious heat, low pH and vanilloid compounds such as capsaicin. Since TRPV1 acts as an integrator of painful stimuli, TRPV1 antagonists can be used as promising therapeutics for new types of analgesics. Areas covered: This review article covers the patents that claim TRPV1 antagonists and were published during 2011 - 2014. The patent evaluation is organized according to the applicant companies, and the representative chemical entities with important in vitro and in vivo data are summarized. Expert opinion: Many pharmaceutical companies showed promising results in the discovery of potent small molecule TRPV1 antagonists, and recently, a number of small molecule TRPV1 antagonists have been advanced into clinical trials. Unfortunately, several candidate molecules showed critical side effects such as hyperthermia and impaired noxious heat sensation in humans, leading to their withdrawal from clinical trials. Some TRPV1 antagonists patented in recent years (2011 - 2014) overcame these undesirable side effects, making the development of TRPV1 antagonists much more promising.</P>
5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATcl expression
( Ju Hee Kang ),( Zheng Ting ),( Mi Ran Moon ),( Jung Seon Sim ),( Jung Min Lee ),( Kyung Eun Doh ),( Sunhye Hong ),( Minghua Cui ),( Sun Choi ),( Hyeun Wook Chang ),( Hea Young Park Choo ),( Mijung Y 영남대학교 약품개발연구소 2016 영남대학교 약품개발연구소 연구업적집 Vol.26 No.-
5-Lipoxygenase synthesizes leukotrienes from arachidonic acid. We developed three novel 5-LO inhibi-tors having a benzoxazole scaffold as a potential anti-osteoclastogenics. They significantly suppressed RANKL-induced osteoclast formation in mouse bone marrow-derived macrophages. Furthermore, one compound. K7, inhibited the bone resorptive activity of osteoclasts. The anti-osteoclastogenic effect of K7 was mainly attributable to reduction in the expression of NFATc1. an essential transcription factor for osteoclast differentiation. K7 inhibited osteoclast formation via ERK and p38 MAPK. as well as NF-KB signaling pathways. K7 reduced lipopolysaccharide (LPS)-induced osteoclast formation in vivo. corroborating the in vitro data. Thus, IG exerted an inhibitory effect on osteoclast formation in vitro and in vivo, properties that make it a potential candidate for the treatment of bone diseases associated with excessive bone resorption.